Japan Tissue Engineering Co.,Ltd. [7774.T]
TOKYO, May 01 (Pulse News Wire) – Japan Tissue Engineering CO.,LTD. (7774.T) reported strong progress in its regenerative medicine products and services.
In the fiscal year ending March 2026, the company achieved revenues of ¥5 billion, driven primarily by its flagship product Jack, which treats osteoarthritis. The firm also secured insurance coverage for its latest product Jasmine, used for treating vitiligo, adding another revenue stream. Japan Tissue Engineering continues to expand its offerings through strategic partnerships and technological advancements. Notably, the company completed the manufacturing and sales approval process for Allo-JaCE03, a dry allogeneic cultured skin equivalent, marking a significant step forward in its pipeline development. Additionally, the firm plans to launch a new intestinal model product aimed at pharmaceutical and food manufacturers, further diversifying its customer base.
Looking ahead, Japan Tissue Engineering aims to capitalize on its proprietary cell-based platform to achieve global growth. Key initiatives include expanding Jack's indications to treat knee osteoarthritis and enhancing its presence in Europe through the establishment of a subsidiary. The company expects to reach annual sales targets of 350 cases for Jack and 100 cases for Jasmine by leveraging existing customer relationships and developing new treatment pathways. In addition to commercial efforts, Japan Tissue Engineering emphasizes human capital management, focusing on employee training and retention strategies to support long-term sustainability. The firm has maintained a positive work environment, evidenced by low turnover rates and high engagement scores among employees.
🟡 Confidence: Standard AI-translated content.